よむ、つかう、まなぶ。
03 資料１－１ 帯状疱疹ワクチンファクトシート (81 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_40826.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第26回 6／20）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
240.
Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit
candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis 2015;
211(8): 1279-87.
241.
Hoshi SL, Kondo M, Okubo I. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic
neuralgia for elderly in Japan. Vaccine 2017; 35(24): 3264-71.
242.
Hoshi SL, Seposo X, Shono A, Okubo I, Kondo M. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and
Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in
Japan. Vaccine 2019; 37(27): 3588-97.
243.
Shiragami M, Mizukami A, Kaise T, et al. Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in
Japanese Adults Aged 65 Years and Older. Dermatol Ther (Heidelb) 2019; 9(2): 281-97.
244.
Teng L, Mizukami A, Ng C, et al. Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster
Vaccine in Japanese Older Adults. Dermatol Ther (Heidelb) 2022; 12(6): 1447-67.
245.
Izurieta HS, Wernecke M, Kelman J, et al. Effectiveness and Duration of Protection Provided by the Liveattenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older. Clin Infect Dis 2017; 64(6):
785-93.
246.
Curran D, Van Oorschot D, Matthews S, Hain J, Salem AE, Schwarz M. Long-term efficacy data for the
recombinant zoster vaccine: impact on public health and cost effectiveness in Germany. Hum Vaccin Immunother
2021; 17(12): 5296-303.
247.
Shiraki K, Toyama N, Tanaka K, Ito A, Yamamoto J, members of the Miyazaki Dermatologist, Society. Effect of
universal varicella vaccination and behavioral changes against coronavirus disease 2019 pandemic on the incidence
of herpes zoster. J Dermatol Sci 2021; 104(3): 185-92.
248.
Mizukami A, Sato K, Adachi K, et al. Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related
Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort Study.
Clin Drug Investig 2018; 38(1): 29-37.
249.
Imafuku S, Nakayama J, Higa K, et al. One-year follow-up of zoster-associated pain in 764 immunocompetent
patients with acute herpes zoster treated with famciclovir (FAMILIAR study). J Eur Acad Dermatol Venereol 2014;
28(12): 1716-22.
250.
Warrington R, Ismail S. Summary of the NACI Update on Herpes Zoster Vaccines. Can Commun Dis Rep 2018;
44(9): 220-5.
251.
Parikh R, Widenmaier R, Lecrenier N. A practitioner's guide to the recombinant zoster vaccine: review of national
vaccination recommendations. Expert Rev Vaccines 2021; 20(9): 1065-75.
252.
Centers for Disease Control Prevention. Update on herpes zoster vaccine: licensure for persons aged 50 through
59 years. MMWR Morb Mortal Wkly Rep 2011; 60(44): 1528.
253.
U.S. Food & Drug Administration. March 24, 2011 Approval Letter - Zostavax. 2011/03/24 2011.
https://wayback.archiveit.org/7993/20170723093313/https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm24860
8.htm (accessed 2024/4/26).
254.
Centers for Disease Control Prevention. Shingrix Recommendations. 2024.
80
Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit
candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis 2015;
211(8): 1279-87.
241.
Hoshi SL, Kondo M, Okubo I. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic
neuralgia for elderly in Japan. Vaccine 2017; 35(24): 3264-71.
242.
Hoshi SL, Seposo X, Shono A, Okubo I, Kondo M. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and
Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in
Japan. Vaccine 2019; 37(27): 3588-97.
243.
Shiragami M, Mizukami A, Kaise T, et al. Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in
Japanese Adults Aged 65 Years and Older. Dermatol Ther (Heidelb) 2019; 9(2): 281-97.
244.
Teng L, Mizukami A, Ng C, et al. Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster
Vaccine in Japanese Older Adults. Dermatol Ther (Heidelb) 2022; 12(6): 1447-67.
245.
Izurieta HS, Wernecke M, Kelman J, et al. Effectiveness and Duration of Protection Provided by the Liveattenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older. Clin Infect Dis 2017; 64(6):
785-93.
246.
Curran D, Van Oorschot D, Matthews S, Hain J, Salem AE, Schwarz M. Long-term efficacy data for the
recombinant zoster vaccine: impact on public health and cost effectiveness in Germany. Hum Vaccin Immunother
2021; 17(12): 5296-303.
247.
Shiraki K, Toyama N, Tanaka K, Ito A, Yamamoto J, members of the Miyazaki Dermatologist, Society. Effect of
universal varicella vaccination and behavioral changes against coronavirus disease 2019 pandemic on the incidence
of herpes zoster. J Dermatol Sci 2021; 104(3): 185-92.
248.
Mizukami A, Sato K, Adachi K, et al. Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related
Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort Study.
Clin Drug Investig 2018; 38(1): 29-37.
249.
Imafuku S, Nakayama J, Higa K, et al. One-year follow-up of zoster-associated pain in 764 immunocompetent
patients with acute herpes zoster treated with famciclovir (FAMILIAR study). J Eur Acad Dermatol Venereol 2014;
28(12): 1716-22.
250.
Warrington R, Ismail S. Summary of the NACI Update on Herpes Zoster Vaccines. Can Commun Dis Rep 2018;
44(9): 220-5.
251.
Parikh R, Widenmaier R, Lecrenier N. A practitioner's guide to the recombinant zoster vaccine: review of national
vaccination recommendations. Expert Rev Vaccines 2021; 20(9): 1065-75.
252.
Centers for Disease Control Prevention. Update on herpes zoster vaccine: licensure for persons aged 50 through
59 years. MMWR Morb Mortal Wkly Rep 2011; 60(44): 1528.
253.
U.S. Food & Drug Administration. March 24, 2011 Approval Letter - Zostavax. 2011/03/24 2011.
https://wayback.archiveit.org/7993/20170723093313/https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm24860
8.htm (accessed 2024/4/26).
254.
Centers for Disease Control Prevention. Shingrix Recommendations. 2024.
80